RenovoRx, Inc. has announced the appointment of Richard Stark to its Board of Directors, effective November 18, 2026. This decision increases the board size from six to seven members, a strategic move that could enhance the company's governance and direction.

Stark, who has over 30 years of experience in the medical technology industry, is expected to bring valuable insights to RenovoRx. His background includes founding and leading various medical technology companies, making him a significant addition to the board.

Background

RenovoRx, Inc. operates in the surgical and medical instruments and apparatus sector, classified under SIC code 3841. The company is listed on the Nasdaq under the ticker RNXT. As a smaller reporting company and an emerging growth entity, RenovoRx focuses on innovative solutions in the medical field.

What the Filing Says

According to the recent SEC filing (accession number 0001493152-26-053335), the board approved Stark's appointment to fill the newly created vacancy. Stark has served as a consultant to the company since December 2024, providing strategic advice and insights.

"The Board has determined that Mr. Stark qualifies as an independent director in accordance with the requirements of the Nasdaq Stock Market LLC," the filing states.

Impact

Stark's extensive experience in medical technology, including leadership roles at companies like Innoblative Designs and Sanarus Technologies, positions him to significantly influence RenovoRx's strategic initiatives. His appointment may also attract attention from investors and stakeholders within the surgical and medical instruments industry.

What's Next

The filing does not specify what happens next following Stark's appointment, but his integration into the board is likely to be closely monitored by industry analysts and investors alike.